EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen und 6 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6664 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Likun Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Se…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bio-Thera Solutions, Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference bevacizumab (EU‐bevacizumab) in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC).

Methods

Patients were randomized 1:1 to BAT1706 plus paclitaxel and carboplatin (BAT1706 arm) or EU‐bevacizumab plus paclitaxel and carboplatin (EU‐bevacizumab arm) given every 3 weeks for six cycles, followed by maintenance therapy with BAT1706 or EU‐bevacizumab. The primary endpoint was overall response rate at week 18 (ORR 18 ). Clinical equivalence was demonstrated if the 90% confidence interval (CI) of the BAT1706:EU‐bevacizumab ORR 18 risk ratio was contained within the predefined equivalence margins of 0.75–1.33 (China National Medical Products Administration requirements), or 0.73–1.36 (US Food and Drug Administration), or if the 95% CI of the ORR 18 risk difference between treatments was contained within the predefined equivalence margin of −0.12 to 0.15 (EMA requirements).

Results

In total, 649 randomized patients (BAT1706, n = 325; EU‐bevacizumab, n = 324) received at least one cycle of combination treatment. The ORR 18 was comparable between the BAT1706 and EU‐bevacizumab arms (48.0% and 44.5%, respectively). The ORR 18 risk ratio of 1.08 (90% CI: 0.94–1.24) and the ORR 18 risk difference of 0.03 (95% CI: −0.04 to 0.11) were within the predefined equivalence margins, demonstrating the biosimilarity of BAT1706 and EU‐bevacizumab. The safety profile of BAT1706 was consistent with that of EU‐bevacizumab and no new safety signals were observed.

Conclusion

In patients with advanced nonsquamous NSCLC, BAT1706 demonstrated clinical equivalence to EU‐bevacizumab in terms of efficacy, safety, pharmacokinetics, and immunogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinDouble-Blind MethodPaclitaxel

Stichwörter der Autor:innen

bevacizumabbiosimilarefficacynonsquamous non-small cell lung cancersafety

Substanzen

BevacizumabBiosimilar PharmaceuticalsCarboplatinPaclitaxel

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangdong, Guangzhou, China.
  • Clinical Medical Research S.C, Veracruz, México.
  • Health and Science University, Adana City Education and Research Hospital, Adana, Turkey.
  • The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China.
  • Trakya University Medical Faculty, Edirne, Turkey.
  • The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.

ORCID-Profile: Ziyi Fu

Förderung

  • Bio-Thera Solutions, Ltd.

Zitieren

APA

Chen, L., Rangel, J. D. G., Cil, T., Li, X., Cicin, I., Shen, Y., Liu, Z., Ozyilkan, O., Igor, B., Chen, J., Oleksandr, K., Chen, Z., Zhang, H., Fu, Z., Dong, Q., Song, S., Yu, J. C., & Zhang, L. (2023). Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study. Cancer Medicine. https://doi.org/10.1002/cam4.6664

Vancouver

Chen L, Rangel JDG, Cil T, Li X, Cicin I, Shen Y, et al. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study. Cancer Medicine. 2023. doi:10.1002/cam4.6664

BibTeX
@article{Chen2023,
  author = {Chen, Likun and Rangel, Jose David Gomez and Cil, Timucin and Li, Xingya and Cicin, Irfan and Shen, Yihong and Liu, Zhihua and Ozyilkan, Ozgur and Igor, Bondarenko and Chen, Jun and Oleksandr, Kostiuk and Chen, Zhendong and Zhang, Helong and Fu, Ziyi and Dong, Qingfeng and Song, Shuqiang and Yu, Jin-Chen and Zhang, Li},
  title = {Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6664}
}
Kostenlos starten →